

Disclosures

Personal Commercial (4)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Kardigan	Research/Research Grants	None (\$0)	
MedAlliance	Research/Research Grants	None (\$0)	
Medtronic	Research/Research Grants	None (\$0)	
Medtronic	Consultant Fees/Honoraria	Significant (>= \$5,000)	Valvular Heart Disease

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
NHLBI	Data Safety Monitoring Board	None (\$0)	

Clinical Trial Enroller (15)

Trial Name	Trial Sponsor	Trial Funding Source
COMPLETE-2	Abbott	
AMPLATZER™ PFO Occluder Post Approval clinical study	Abbott Cardiovascular Systems, Inc	
CORE PRECISION International Study	Canon Medical Systems	
EMPOWER Trial	Cardiac Dimensions	
STICH3C	Cornell University	
RECHARGE Trial	Cornell University	
Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP II TR)	Edwards Lifesciences	
Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device Short Title: TRISCEND II Pivotal Trial	Edwards Lifesciences	
Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System in Patients at Low Risk For Surgical Aortic Valve Replacement Continued Access Study	MEDTRONIC	
APOLLO Trial-Transcatheter Mitral Valve Replacement with the Medtronic Intrepid™ TMVR System in patients with severe symptomatic mitral regurgitation	MEDTRONIC	
Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement	MEDTRONIC	
Evolut EXPAND TAVR II Pivotal Trial	MEDTRONIC	
SPYRAL AFFIRM	MEDTRONIC	
RESTORE Trial	MEDTRONIC	
PRIMARY Trial	NHLBI	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (6)

Year	Case Title	Represented	Description	Compensation
Self				

Year	Case Title	Represented	Description	Compensation
2025	Death after diagnostic coronary angiography	Defendant		Significant (>= \$5,000)
2025	Myocardial infarction	Defendant		Significant (>= \$5,000)
2025	Papillary fibroelastoma	Defendant		Modest (< \$5,000)
2025	Iatrogenic coronary dissection	Plaintiff		Modest (< \$5,000)
2025	Possible missed MI	Defendant		Modest (< \$5,000)
2025	Vascular complication during TAVR	Defendant		Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

- Certified Education Attestation** | Signed on 12/28/2025
URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>
- Confidentiality, Disclosure and Assignment Agreement** | Signed on 12/28/2025
URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>
- Embargo** | Signed on 12/28/2025
URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>
- On-Going Obligation Agreement** | Signed on 12/28/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.